EASL Clinical Practice Guidelines: Drug-induced liver injury

Andrade, Raúl J.; Aithal, Guruprasad P.; Björnsson, Einar S.; Kaplowitz, Neil; Kullak-Ublick, Gerd A.; Larrey, Dominique; Karlsen, Tom H.

doi:10.1016/j.jhep.2019.02.014

Cited by 1,278Drug-Induced Hepatotoxicity and ProtectionLiver Diseases and ImmunityPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index, and 1 are not checked yet.

EASL Clinical Practice Guidelines: Drug-induced liver injury

Andrade, Raúl J., Aithal, Guruprasad P., Björnsson, Einar S., Kaplowitz, Neil, Kullak-Ublick, Gerd A., Larrey, Dominique, Karlsen, Tom H.·2019·Journal of Hepatology

DOI 10.1016/j.jhep.2019.02.014

Open this paper in CoChat — free account

Abstract

Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.02.014

Cites

366 of 367 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs and other chemicals, including herbal and dietary supplements (HDS).
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
The vast majority of DILI cases occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and are unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual.
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In pediatric medicine, DILI is rare but has high morbidity and mortality and is one of the most common causes of acute liver failure; diagnosis is challenging due to low incidence and phenotypic variability.
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage DI-ALH.
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]

Drug rechallenge in DILI cases is potentially dangerous and is associated with risk of death or requirement for liver transplant.
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI.
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery.
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
RUCAM is the most widely used tool for causality assessment in DILI.
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
The potential value of glutamate dehydrogenase in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin has been evaluated.
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Fundamentals of Biostatistics.
Cornell, R. G., & ROSNER, B. A. (1987) · Journal of the American Statistical Association · doi:10.2307/2289416 · Cited by 1,613
Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature
Casagranda, A., Suppa, M., Dehavay, F., & del Marmol, V. (2017) · Case Reports in Dermatology · doi:10.1159/000475802 · Cited by 1,466
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citation
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
EASL Clinical Practice Guidelines: Wilson’s disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.007 · Cited by 1,239
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 1,171
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Self-citation
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe’er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 1,050
Self-citation
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Self-citation
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
Kardaun, S. H., Sidoroff, A., Valeyrie‐Allanore, L., Halevy, S., Davidovici, B. B., Mockenhaupt, M., & Roujeau, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07704.x · Cited by 943
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
Self-citation
Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Self-citation
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C. M., van der Ven, A. J. A. M., & Dekhuijzen, R. P. N. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 813
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
RUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Incidence of drug-induced hepatic injuries: A French population-based study
Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., Lenoir, C., Lemoine, A., & Hillon, P. (2002) · Hepatology · doi:10.1053/jhep.2002.34857 · Cited by 716
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M. K., Konto, C., & Wolchok, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 713
Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily
Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., & Harris, S. (2006) · JAMA · doi:10.1001/jama.296.1.87 · Cited by 631
Self-citation
Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities.
Gonzalez-Quintela, A., Alende, R., Gude, F., Campos, J., Rey, J., Meijide, L. M., Fernandez-Merino, C., & Vidal, C. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03545.x · Cited by 630
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure
Lee, W. M., Hynan, L. S., Rossaro, L., Fontana, R. J., Stravitz, R. T., Larson, A. M., Davern, T. J., Murray, N. G., McCashland, T., Reisch, J. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.006 · Cited by 607
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
Waterbeemd, H. V. D., Smith, D. A., Beaumont, K. C., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 600
AGA technical review on the evaluation of liver chemistry tests
Green, R. M., & Flamm, S. L. (2002) · Gastroenterology · doi:10.1053/gast.2002.36061 · Cited by 589
Epidemiology of Hepatocellular Adenoma
Rooks, J. B. (1979) · JAMA · doi:10.1001/jama.1979.03300070040020 · Cited by 589
Pyrrolizidine Alkaloids—Genotoxicity, Metabolism Enzymes, Metabolic Activation, and Mechanisms
Fu, P. P., Xia, Q., Lin, G., & Chou, M. W. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028426 · Cited by 582
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver
Stieger, B., Fattinger, K. E., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 577
Self-citation
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.033 · Cited by 520
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese
Man, C. B. L., Kwan, P., Baum, L., Yu, E., Lau, K., Cheng, A. S., & Ng, M. H. L. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01022.x · Cited by 506
Schiff's Diseases of the Liver
(2017) · Wiley eBooks · doi:10.1002/9781119251316 · Cited by 503
Hepatitis E
Hoofnagle, J. H., Nelson, K. E., & Purcell, R. H. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204512 · Cited by 492
Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge
Benichou, C., Danan, G., & Flahault, A. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90102-7 · Cited by 491
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A. R., Clarke, S. E., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H., Naisbitt, D. J., Nelson, S. D., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 466
Liver injury from herbal and dietary supplements
Navarro, V. J., Khan, I. A., Bjornsson, E. S., Seeff, L. B., Serrano, J., & Hoofnagle, J. H. (2016) · Hepatology · doi:10.1002/hep.28813 · Cited by 462
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore, T. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1752 · Cited by 461
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · CHEST Journal · doi:10.1378/chest.99.2.465 · Cited by 454
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz–Cabello, F., Donaldson, P. T., Stephens, C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.001 · Cited by 442
Self-citation
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Self-citation
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis
Björnsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P. S., Takahashi, N., Sanderson, S., Neuhauser, M., & Lindor, K. (2010) · Hepatology · doi:10.1002/hep.23588 · Cited by 436
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J. T., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 410
Self-citation
Acute and clinically relevant drug‐induced liver injury: a population based case‐control study
de Abajo, F. J., Montero, D., Madurga, M., & Rodríguez, L. A. G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02133.x · Cited by 408
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations
Kleiner, D. E., Chalasani, N. P., Lee, W. M., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Hayashi, P. H., Davern, T. J., Navarro, V., Reddy, R., et al. (2014) · Hepatology · doi:10.1002/hep.26709 · Cited by 396
Liver transplantation for acute liver failure from drug induced liver injury in the United States
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. (2004) · Liver Transplantation · doi:10.1002/lt.20204 · Cited by 393
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals
Lammert, C. S., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E. S., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22272 · Cited by 389
Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity
Swift, B., Pfeifer, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 381
Ischemic hepatitis: clinical presentation and pathogenesis
Seeto, R. K., Fenn, B., & Rockey, D. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00461-7 · Cited by 362
Hy's law: predicting serious hepatotoxicity
Temple, R. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1211 · Cited by 353
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
Maria, V. A., & Victorino, R. M. (1997) · Hepatology · doi:10.1002/hep.510260319 · Cited by 351
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. I. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 350
Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348
Self-citation
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Valproic acid hepatic fatalities. III. U.S. experience since 1986
Bryant, A. E., & Dreifuss, F. E. (1996) · Neurology · doi:10.1212/wnl.46.2.465 · Cited by 339
The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors
Byrne, J. A., Strautnieks, S. S., Mieli‐Vergani, G., Higgins, C. F., Linton, K. J., & Thompson, R. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36591 · Cited by 337
Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development
Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., & Hamadeh, H. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq269 · Cited by 325
Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury
Davern, T. J., Chalasani, N., Fontana, R. J., Hayashi, P. H., Protiva, P., Kleiner, D. E., Engle, R. E., Nguyen, H., Emerson, S. U., Purcell, R. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.051 · Cited by 324
Mechanisms of drug-induced liver injury
Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322
Self-citation
In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans
Dawson, S., Stahl, S. H., Paul, N. R., Barber, J., & Kenna, J. G. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 321
Standardization of nomenclature and causality assessment in drug‐induced liver injury
Fontana, R. J., Seeff, L. B., Andrade, R. J., Bjornsson, E. S., Day, C. P., Serrano, J., & Hoofnagle, J. H. (2010) · Hepatology · doi:10.1002/hep.23696 · Cited by 320
Self-citation
Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy
KEPPLER, D. O. R. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_8 · Cited by 316
Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management
Núñez, M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.027 · Cited by 315
Causality Assessment in Drug-Induced Liver Injury Using A Structured Expert Opinion Process: Comparison to the Roussel-Uclaf Causality Assessment Method
Rockey, D. C., Seeff, L. B., Rochon, J., Freston, J., Chalasani, N., Bonacini, M., Fontana, R. J., & Hayashi, P. H. (2010) · Hepatology · doi:10.1002/hep.23577 · Cited by 313
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis
Rubbia‐Brandt, L., Lauwers, G. Y., Wang, H., Majno, P. E., Tanabe, K., Zhu, A. X., Brézault, C., Soubrane, O., Abdalla, E. K., Vauthey, J., et al. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03511.x · Cited by 311
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury
Suzuki, A., Brunt, E. M., Kleiner, D. E., Miquel, R., Smyrk, T. C., Andrade, R. J., Lucena, I. M., Castiella, A., Lindor, K., & Björnsson, E. (2011) · Hepatology · doi:10.1002/hep.24481 · Cited by 310
Self-citation
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry
Andrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Self-citation
New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune System
Uetrecht, J. (1999) · Chemical Research in Toxicology · doi:10.1021/tx980249i · Cited by 307
Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis
Iorga, A., Dara, L., & Kaplowitz, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051018 · Cited by 305
Self-citation
Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.022 · Cited by 304
Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury
Robles–Diaz, M., Lucena, M. I., Kaplowitz, N., Stephens, C., Medina–Cáliz, I., González–Jimenez, A., Ulzurrun, E., Gonzalez, A. F., Fernandez, M. C., Romero–Gómez, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.050 · Cited by 301
Self-citation
Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat
Funk, C., Ponelle, C., Scheuermann, G., & Pantze, M. P. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.3.627 · Cited by 295
Phenotypic characterization of idiosyncratic drug‐induced liver injury: The influence of age and sex†
Lucena, M. I., Andrade, R. J., Kaplowitz, N., García‐Cortes, M., Fernández, M. C., Romero‐Gomez, M., Bruguera, M., Hallal, H., Robles‐Diaz, M., Rodriguez‐González, J. F., et al. (2009) · Hepatology · doi:10.1002/hep.22895 · Cited by 290
Self-citation
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S. R., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity
Saito, C., Lemasters, J. J., & Jaeschke, H. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.04.015 · Cited by 273
Carnitine in the treatment of valproic acid-induced toxicity
Lheureux, P. E. R., & Hantson, P. E. (2009) · Clinical Toxicology · doi:10.1080/15563650902752376 · Cited by 273
Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients
Lewis, J. H., Ranard, R. C., Caruso, A. C., Jackson, L. K., Mullick, F. G., Ishak, K. G., Seeff, L. B., & Zimmerman, H. J. (1989) · Hepatology · doi:10.1002/hep.1840090504 · Cited by 265
Carnitine deficiency and hyperammonemia associated with valproic acid therapy
Ohtani, Y., Endo, F., & Matsuda, I. (1982) · The Journal of Pediatrics · doi:10.1016/s0022-3476(82)80320-x · Cited by 263
Liver Investigation in 149 Asymptomatic Patients with Moderately Elevated Activities of Serum: Aminotransferases
Hultcrantz, R., Glaumann, H., Lindberg, G., & Nilsson, L. H. (1986) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528609034632 · Cited by 261
Nodular regenerative hyperplasia: Not all nodules are created equal
Reshamwala, P. A., Kleiner, D. E., & Heller, T. (2006) · Hepatology · doi:10.1002/hep.21258 · Cited by 258
Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats
Misra, P. S., Lefèvre, A., Ishii, H., Rubin, E., & Lieber, C. S. (1971) · The American Journal of Medicine · doi:10.1016/0002-9343(71)90270-1 · Cited by 257
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E. A., Chrisman, C. R., & Self, T. H. (2005) · CHEST Journal · doi:10.1378/chest.128.1.116 · Cited by 254
Oral contraceptive use and focal nodular hyperplasia of the liver
Mathieu, D. G., Kobeiter, H., Maison, P., Rahmouni, A., Cherqui, D., Zafrani, É. S., & Dhumeaux, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70262-9 · Cited by 253
Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future
Senior, J. R. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.108 · Cited by 252
Oral Medications With Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events
Lammert, C. S., Bjornsson, E. S., Niklasson, A., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.23317 · Cited by 251
Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports
Björnsson, E. S., & Hoofnagle, J. H. (2016) · Hepatology · doi:10.1002/hep.28323 · Cited by 245
Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.
Guy, J. E., & Peters, M. G. (2013) · Europe PMC (PubMed Central) · Cited by 244
Polymerase γ Gene POLG Determines the Risk of Sodium Valproate-Induced Liver Toxicity
Stewart, J. D., Horváth, R., Baruffini, E., Ferrero, I., Bulst, S., Watkins, P. B., Fontana, R. J., Day, C. P., & Chinnery, P. F. (2010) · Hepatology · doi:10.1002/hep.23891 · Cited by 242
Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum
Lin, G., Wang, J. Y., Li, N., Li, M., Gao, H., Ji, Y., Zhang, F., Wang, H., Zhou, Y., Ye, Y., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.031 · Cited by 241
Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions
Velazquez, I., & Alter, B. P. (2004) · American Journal of Hematology · doi:10.1002/ajh.20183 · Cited by 234
Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort
Church, R. J., Kullak‐Ublick, G. A., Aubrecht, J., Bonkovsky, H. L., Chalasani, N., Fontana, R. J., Goepfert, J. C., Hackman, F., King, N. M. P., Kirby, S., et al. (2019) · Hepatology · doi:10.1002/hep.29802 · Cited by 231
Self-citation
Performance parameters of the diagnostic scoring systems for autoimmune hepatitis
Czaja, A. J. (2008) · Hepatology · doi:10.1002/hep.22513 · Cited by 223
A prospective nationwide study of drug-induced liver injury in Korea
Suk, K. T., Kim, D. J., Kim, C. H., Park, S. H., Yoon, J. H., Kim, Y. S., Baik, G. H., Kim, J. B., Kweon, Y. O., Kim, B. I., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.138 · Cited by 221
Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study
Nicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., Barnhart, H. X., Bondon-Guitton, E., Hayashi, P. H., Bessone, F., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.016 · Cited by 221
Self-citation
The role of hepatitis E virus testing in drug‐induced liver injury
Dalton, H. R., Fellows, H. J., Stableforth, W., JOSEPH, M., Thurairajah, P. H., Warshow, U. M., Hazeldine, S., Remnarace, R., Ijaz, S., Hussaini, S. H., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03504.x · Cited by 219
Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset
Fontana, R. J., Hayashi, P. H., Gu, J., Reddy, K. R., Barnhart, H., Watkins, P. B., Serrano, J., Lee, W. M., Chalasani, N., Stolz, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.045 · Cited by 218
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump
Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
Acetaminophen Toxicity: Novel Insights Into Mechanisms and Future Perspectives
Ramachandran, A., & Jaeschke, H. (2017) · Gene Expression · doi:10.3727/105221617x15084371374138 · Cited by 215
Comparison of Two Clinical Scales for Causality Assessment in Hepatotoxicity
Lucena, M. I., Camargo, R., Andrade, R. J., Perez-Sanchez, C. J., & De La Cuesta, F. S. (2001) · Hepatology · doi:10.1053/jhep.2001.20645 · Cited by 212
Self-citation
Fatal Liver Disease after Intravenous Administration of Tetracycline in High Dosage
Schultz, J. C., Adamson, J. S., Workman, W. W., & Norman, T. D. (1963) · New England Journal of Medicine · doi:10.1056/nejm196311072691903 · Cited by 212
Ipilimumab-associated Hepatitis
Johncilla, M. E., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000453 · Cited by 208
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
Bruno, S., Maisonneuve, P., Castellana, P., Rotmensz, N., Rossi, S., Maggioni, M., Persico, M., Colombo, A., Monasterolo, F., Casadei-Giunchi, D., et al. (2005) · BMJ · doi:10.1136/bmj.38391.663287.e0 · Cited by 201
The natural history of histologically proved drug induced liver disease
Aithal, G. P., & Day, C. P. (1999) · Gut · doi:10.1136/gut.44.5.731 · Cited by 199
Self-citation
Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria
Han, D., Dara, L., Win, S., Than, T. A., Yuan, L., Abbasi, S. Q., Liu, Z., & Kaplowitz, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.009 · Cited by 198
Self-citation
Steroid Use in Acute Liver Failure
Karkhanis, J., Verna, E. C., Chang, M. S., Stravitz, R. T., Schilsky, M. L., Lee, W. M., & Brown, R. S. (2013) · Hepatology · doi:10.1002/hep.26678 · Cited by 196
Single-Center Experience With Drug-Induced Liver Injury From India: Causes, Outcome, Prognosis, and Predictors of Mortality
Devarbhavi, H., Dierkhising, R., Kremers, W. K., Sandeep, M. S., Karanth, D., & Adarsh, C. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.287 · Cited by 195
Incidence of drug-induced liver injury in medical inpatients
Meier, Y., Cavallaro, M., Roos, M., Pauli‐Magnus, C., Folkers, G., Meier, P. J., & Fattinger, K. E. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0888-z · Cited by 194
Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury†
Lucena, M. I., Andrade, R. J., Martínez, C., Ulzurrun, E., García‐Martín, E., Borraz, Y., Fernández, M. C., Romero‐Gómez, M., Castiella, A., Planas, R., et al. (2008) · Hepatology · doi:10.1002/hep.22370 · Cited by 194
Self-citation
c‐Jun N‐terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)‐dependent pathway leading to inactivation of intramitochondrial Src
Win, S., Than, T. A., Min, R. W. M., Aghajan, M., & Kaplowitz, N. (2016) · Hepatology · doi:10.1002/hep.28486 · Cited by 191
Self-citation
Features of autoimmune hepatitis in patients with drug-induced liver injury
de Boer, Y. S., Kosinski, A. S., Urban, T. J., Zhao, Z., Long, N., Chalasani, N., Kleiner, D. E., & Hoofnagle, J. H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.043 · Cited by 190
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189
Effect of l -carnitine treatment for valproate-induced hepatotoxicity
Bohan, T. P., Helton, E. D., McDonald, I., König, S. A., Gazitt, S., Sugimoto, T., Scheffner, D., Cusmano, L., Li, S., & Koch, G. G. (2001) · Neurology · doi:10.1212/wnl.56.10.1405 · Cited by 188
Troglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. A. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 187
Drug metabolism alterations in nonalcoholic fatty liver disease
Merrell, M. D., & Cherrington, N. J. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.577781 · Cited by 187
Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment
Rosenberg, P., Urwitz, H., Johannesson, A., Ros, A.-M., Lindholm, J., Kinnman, N., & Hultcrantz, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.024 · Cited by 185
Acute liver failure in Sweden: etiology and outcome
Wei, G., Bergquist, A. M., Broomé, U., Lindgren, S. C., Wallerstedt, S. M., Almer, S. H., Sangfelt, P., Danielsson, A., Sandberg–Gertzén, H., Lööf, L., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01818.x · Cited by 185
Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study
Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H., & Okutani, Y. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500442 · Cited by 184
Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
Vernier‐Massouille, G., Cosnes, J., Lémann, M., Marteau, P. R., Reinisch, W., Laharie, D., Cadiot, G., Bouhnik, Y., Vos, M. D., Boureille, A., et al. (2007) · Gut · doi:10.1136/gut.2006.114363 · Cited by 183
Drug-induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia
Degott, C., Feldmann, G., Larrey, D. G., Durand‐Schneider, A., Grangè, J. D., Machayekhi, J.-P., Moreau, A., Potet, F., & Benhamou, J. (1992) · Hepatology · doi:10.1002/hep.1840150212 · Cited by 183
Self-citation
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics
García-Cortés, M., Robles-Díaz, M., Ortega-Alonso, A., Medina-Caliz, I., & Andrade, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040537 · Cited by 179
Self-citation
Drug‐induced liver injury in a Swedish University hospital out‐patient hepatology clinic
DE VALLE, M. B., AV KLINTEBERG, V., ALEM, N., OLSSON, R., & BJÖRNSSON, E. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03117.x · Cited by 179
Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the Literature
Falcó, V., Rodríguez-Pardo, D., Ribera, E., Martínez, E., Miró, J. M., Domingo, P., Diazaraque, R., Arribas, J. R., González‐García, J., Montero, F., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339041 · Cited by 179
Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension
Hartleb, M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i11.1400 · Cited by 177
Hepatotoxicity associated with antiepileptic drugs
Bjornsson, E. S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01009.x · Cited by 176
Untitled work
Lheureux (2005) · doi:10.1186/cc3742 · Cited by 176
Enterohepatic transport of bile salts and genetics of cholestasis
Pauli‐Magnus, C., Stieger, B., Meier, Y., Kullak-Ublick, G. A., & Meier, P. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.017 · Cited by 175
Self-citation
Vanishing bile duct syndrome in drug-induced liver disease
Desmet, V. J. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)82330-6 · Cited by 174
Hepatotoxicity related to antirheumatic drugs
Aithal, G. P. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.214 · Cited by 170
Self-citation
Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells
Anthérieu, S., Rogue, A., Fromenty, B., Guillouzo, A., & Robin, M. (2011) · Hepatology · doi:10.1002/hep.24290 · Cited by 168
A prospective study of the causes of notably raised aspartate aminotransferase of liver origin
Whitehead, M. W., Hawkes, N., Hainsworth, I. R., & Kingham, J. G. C. (1999) · Gut · doi:10.1136/gut.45.1.129 · Cited by 166
Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome
Helmy, A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02742.x · Cited by 164
Apoptosis and necrosis in liver disease
Jaeschke, H., Gujral, J. S., & Bajt, M. L. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0906.x · Cited by 161
The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis
Tapper, E. B., Sengupta, N., & Bonder, A. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.033 · Cited by 159
Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial
Squires, R. H., Dhawan, A., Alonso, E., Narkewicz, M. R., Shneider, B. L., Rodriguez-Baez, N., Olio, D. D., Karpen, S., Bucuvalas, J., Lobritto, S., et al. (2013) · Hepatology · doi:10.1002/hep.26001 · Cited by 159
Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment–Induced Hepatotoxicity
Sharma, S. K., Singla, R., Sarda, P., Mohan, A., Makharia, G. K., Jayaswal, A., Sreenivas, V., & Singh, S. (2010) · Clinical Infectious Diseases · doi:10.1086/650576 · Cited by 159
The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug‐induced liver injury
Bjornsson, E. S., Kalaitzakis, E., & Olsson, R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03330.x · Cited by 158
Risk Factors for Development of Cholestatic Drug-Induced Liver Injury: Inhibition of Hepatic Basolateral Bile Acid Transporters Multidrug Resistance-Associated Proteins 3 and 4
Köck, K., Ferslew, B. C., Netterberg, I., Yang, K., Urban, T. J., Swaan, P. W., Stewart, P. W., & Brouwer, K. L. R. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054304 · Cited by 158
Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy?
Ludwig, J., Kim, C. H., Wiesner, R. H., & Krom, R. A. F. (1989) · Hepatology · doi:10.1002/hep.1840090209 · Cited by 155
Drug‐induced liver injury at an Asian center: a prospective study
Wai, C. T., Tan, B., Chan, C., Sutedja, D. S., Lee, Y.-M., Khor, C. J. L., & Lim, S. G. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01461.x · Cited by 152
Causality Assessment Versus Guilt–By–Association in Drug Hepatotoxicity
Kaplowitz, N. (2001) · Hepatology · doi:10.1053/jhep.2001.21083 · Cited by 152
Self-citation
The Clinical Significance of Slightly to Moderately Increased Liver Transaminase Values in Asymptomatic Patients
Mathiesen, U. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529950172880 · Cited by 150
Fatty liver of pregnancy and its relationship to tetracycline therapy
Kunelis, C. T., Peters, J. L., & Edmondson, H. A. (1965) · The American Journal of Medicine · doi:10.1016/0002-9343(65)90145-2 · Cited by 148
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
Kleiner, D. E., & Berman, D. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2140-5 · Cited by 148
Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome
McGill, M. R., Staggs, V. S., Sharpe, M. R., Lee, W. M., & Jaeschke, H. (2014) · Hepatology · doi:10.1002/hep.27265 · Cited by 148
Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data
Wang, W., Lie, P., Guo, M., & He, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30678 · Cited by 147
Etiology of New-Onset Jaundice: How Often Is It Caused by Idiosyncratic Drug-Induced Liver Injury in The United States?
Vuppalanchi, R., Liangpunsakul, S., & Chalasani, N. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01019.x · Cited by 146
Drug-induced liver injury: an overview over the most critical compounds
Bjornsson, E. S. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1456-2 · Cited by 142
MRP2 haplotypes confer differential susceptibility to toxic liver injury
Choi, J. H., Ahn, B. M., Yi, J., Lee, J. H., Lee, J. H., Nam, S. W., Chon, C. Y., Han, K., Ahn, S. H., Jang, I., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000236337.41799.b3 · Cited by 141
Hepatic granulomas: histological and molecular pathological approach to differential diagnosis–a study of 442 cases
Drebber, U., Kasper, H., Ratering, J., Wedemeyer, I., Schirmacher, P., Dienes, H., & Odenthal, M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01695.x · Cited by 140
Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications
Dara, L., Liu, Z., & Kaplowitz, N. (2015) · Liver International · doi:10.1111/liv.12988 · Cited by 140
Self-citation
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
Medina-Caliz, I., Robles-Diaz, M., Garcia-Muñoz, B., Stephens, C., Ortega-Alonso, A., Garcia-Cortes, M., González-Jimenez, A., Sanabria-Cabrera, J. A., Moreno, I., Fernandez, M. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.003 · Cited by 140
Self-citation
Liver damage from flucloxacillin, cloxacillin and dicloxacillin
Olsson, R., Wiholm, B. ‐., Sand, C., Zettergren, L., Hultcrantz, R., & Myrhed, M. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90029-o · Cited by 139
Acetaminophen hepatoxicity: What do we know, what don’t we know, and what do we do next?†
Kaplowitz, N. (2004) · Hepatology · doi:10.1002/hep.20312 · Cited by 138
Self-citation
Mechanisms of isoniazid‐induced idiosyncratic liver injury: Emerging role of mitochondrial stress
Boelsterli, U. A., & Lee, K. K. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12516 · Cited by 137
Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients
Mallet, V. O., Blanchard, P., Verkarre, V., Vallet‐Pichard, A., Fontaine, H., Lascoux‐Combe, C., & Pol, S. (2006) · AIDS · doi:10.1097/qad.0b013e3280119e47 · Cited by 137
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements
Bonkovsky, H. L., Kleiner, D. E., Gu, J., Odin, J. A., Russo, M. W., Navarro, V. M., Fontana, R. J., Ghabril, M. S., Barnhart, H., Hoofnagle, J. H., et al. (2017) · Hepatology · doi:10.1002/hep.28967 · Cited by 137
Liver cell adenoma and liver cell adenomatosis
Barthelmes, L., & Tait, I. S. (2005) · HPB · doi:10.1080/13651820510028954 · Cited by 136
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham, D. J. (2001) · JAMA · doi:10.1001/jama.286.7.831 · Cited by 136
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps
Teschke, R., & Eickhoff, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00072 · Cited by 132
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions
Aithal, G. P., Rawlins, M. D., & Day, C. P. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80127-0 · Cited by 132
Self-citation
The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice
Björnsson, E., & Davidsdottir, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.021 · Cited by 131
The placebo effect in healthy volunteers: Influence of experimental conditions on the adverse events profile during phase I studies
Rosenzweig, P., Brohier, S., & Zipfel, A. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.190 · Cited by 128
Drug-Induced Liver Injury with Autoimmune Features
Foureau, D., Jacobs, C., Ahrens, W., Russo, M., Bonkovsky, H. L., & deLemos, A. S. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1375959 · Cited by 126
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B *35:02 as a risk factor
Urban, T. J., Nicoletti, P., Chalasani, N., Serrano, J., Stolz, A., Daly, A. K., Aithal, G. P., Dillon, J., Navarro, V., Odin, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.010 · Cited by 124
Self-citation
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden
Björnsson, E., Jerlstad, P., Bergqvist, A., & Olsson, R. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510023846 · Cited by 123
Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges
Senior, J. R. (2014) · Drug Safety · doi:10.1007/s40264-014-0182-7 · Cited by 123
Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure
Kortsalioudaki, C., Taylor, R. M., Cheeseman, P., Bansal, S., Mieli‐Vergani, G., & Dhawan, A. K. (2007) · Liver Transplantation · doi:10.1002/lt.21246 · Cited by 123
Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis
Moradpour, D., Altorfer, J., Flury, R., Greminger, P., Meyenberger, C. M., Jost, R., & Schmid, M. (1994) · Hepatology · doi:10.1002/hep.1840200610 · Cited by 123
Death and liver transplantation within 2 years of onset of drug‐induced liver injury
Hayashi, P. H., Rockey, D. C., Fontana, R. J., Tillmann, H. L., Kaplowitz, N., Barnhart, H. X., Gu, J., Chalasani, N. P., Reddy, K. R., Sherker, A. H., et al. (2017) · Hepatology · doi:10.1002/hep.29283 · Cited by 123
Self-citation
Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies
Dear, J. W., Clarke, J. I., Francis, B., Allen, L., Wraight, J., Shen, J., Dargan, P. I., Wood, D., Cooper, J., Thomas, S. H. L., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30266-2 · Cited by 123
The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware
For the Drug Induced Liver Injury Network (DILIN), Vega, M., Verma, M., Beswick, D., Bey, S., Hossack, J., Merriman, N., Shah, A., & Navarro, V. (2017) · Drug Safety · doi:10.1007/s40264-017-0547-9 · Cited by 120
Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients
McGill, M. R., & Jaeschke, H. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.920823 · Cited by 119
Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease
Rabinowich, L., & Shibolet, O. (2015) · BioMed Research International · doi:10.1155/2015/168905 · Cited by 118
Risk of drug-induced liver injury from tumor necrosis factor antagonists
Björnsson, E. S., Gunnarsson, B. I., Gröndal, G., Jonasson, J. G., Einarsdottir, R., Ludviksson, B. R., Gudbjörnsson, B., & Olafsson, S. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.062 · Cited by 118
Metabolic activation in drug-induced liver injury
Leung, L. Y., Kalgutkar, A. S. S., & Obach, R. S. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.605791 · Cited by 117
Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis
Cai, Y., Yi, J., Zhou, C., & Shen, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047769 · Cited by 116
Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury
Lucena, M. I., García‐Martín, E., Andrade, R. J., Martínez, C., Stephens, C. M., Buitrago, J. D. R., Ulzurrun, E., Fernandez, C. M., Romero‐Gómez, M., Castiella, A., et al. (2010) · Hepatology · doi:10.1002/hep.23668 · Cited by 115
Self-citation
METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED
He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., & Woolf, T. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.639 · Cited by 115
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
Foureau, D., Walling, T. L., Maddukuri, V. C., Anderson, W. E., Culbreath, K., Kleiner, D. E., Ahrens, W. A., Jacobs, C., Watkins, P. B., Fontana, R. J., et al. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12558 · Cited by 115

Flagged first, then by citations

4 of the 371 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
US Food & Drug Administration, 2017, Drugs
Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278

Sorted by citations

COVID-19: Abnormal liver function tests
Cai, Q., Huang, D., Yu, H., Zhu, Z., Zhang, X., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.006 · Cited by 1,096
Drug-induced liver injury
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citation
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citation
COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China
Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Zhang, X., Su, Y., Ma, Z., Zhang, Y., Li, Z., et al. (2020) · Allergy · doi:10.1111/all.14309 · Cited by 507
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 396
Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
Gao, W., Guo, L., Yang, Y., Wang, Y., Xia, S., Gong, H., Zhang, B., & Yan, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809952 · Cited by 358
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
Trebicka, J., Fernández, J., Papp, M., Caraceni, P., Laleman, W., Gambino, C. G., Giovo, I., Uschner, F. E., Jansen, C., Jiménez, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.019 · Cited by 316
Drug induced liver injury: an update
García‐Cortés, M., Robles‐Díaz, M., Stephens, C. M., Ortega‐Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 306
Self-citation
Superoxide Dismutase Administration: A Review of Proposed Human Uses
Rosa, A. C., Corsi, D., Cavi, N., Bruni, N., & Dosio, F. (2021) · Molecules · doi:10.3390/molecules26071844 · Cited by 297
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 280
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
Paz, M. V., Morán, L., López‐Alcántara, N., Freixo, C., Andrade, R. J., Lucena, M. I., & Cubero, F. J. (2021) · Antioxidants · doi:10.3390/antiox10030390 · Cited by 234
Self-citation
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management
Björnsson, H., & Björnsson, E. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.035 · Cited by 212
Self-citation
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Sun, H., Zhou, J., Wang, Z., Liu, X., Xie, Q. M., Jia, W., Zhao, M. D., Bi, X., Gong, L., Bai, X., et al. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-328 · Cited by 210
A human liver organoid screening platform for DILI risk prediction
Zhang, C. J., Meyer, S. R., O’Meara, M. J., Huang, S., Capeling, M. M., Ferrer-Torres, D., Childs, C. J., Spence, J. R., Fontana, R. J., & Sexton, J. Z. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.019 · Cited by 200
The exposome and liver disease - how environmental factors affect liver health
Barouki, R., Samson, M., Blanc, É., Colombo, M. G., Zucman‐Rossi, J., Lazaridis, K. N., Miller, G. W., & Coumoul, X. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.034 · Cited by 189
Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury
Niu, B., Lei, X., Xu, Q., Ju, Y., Xu, D., Mao, L., Li, J., Zheng, Y., Sun, N., Zhang, X., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09624-x · Cited by 186
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Self-citation
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
Martin, E. D., Michot, J., Rosmorduc, O., Guettier, C., & Samuel, D. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100170 · Cited by 181
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
Mostafa, A., Kandeil, A., Elshaier, Y. A. M. M., Kutkat, O., Moatasim, Y., Rashad, A. A., Shehata, M., Gomaa, M. R., Mahrous, N., Mahmoud, S. H., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13120443 · Cited by 175
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment
Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 175
Incidence and risk factors of drug‐induced liver injury
Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis
Dalekos, G., Gatselis, N., Drenth, J. P. H., Heneghan, M., Jørgensen, M., Lohse, A. W., Londoño, M., Muratori, L., Papp, M., Samyn, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.017 · Cited by 170
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citation
A revised electronic version of RUCAM for the diagnosis of DILI
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez‐Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., et al. (2022) · Hepatology · doi:10.1002/hep.32327 · Cited by 160
Self-citation
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Stephens, C., Robles-Diaz, M., Medina-Caliz, I., Garcia-Cortes, M., Ortega-Alonso, A., Sanabria-Cabrera, J., Gonzalez-Jimenez, A., Alvarez-Alvarez, I., Slim, M., Jimenez-Perez, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.029 · Cited by 148
Self-citation
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
Fu, S., Wu, D., Jiang, W., Li, J., Jiang, L., Jia, C., & Zhou, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01667 · Cited by 148
Oxidative Stress–Induced Liver Damage and Remodeling of the Liver Vasculature
Banerjee, P., Gaddam, N., Chandler, V., & Chakraborty, S. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.06.002 · Cited by 145
EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy
Williamson, C., Nana, M., Poon, L. C., Kupčinskas, L., Painter, R. C., Taliani, G., Heneghan, M. A., Marschall, H., & Beuers, U. H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.006 · Cited by 145
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
Wong, G. L., Wong, V. W., Thompson, A. J. V., Jia, J., Hou, J., Lesmana, C. R. A., Susilo, A., Tanaka, Y., Chan, W., Gane, E. J., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30190-4 · Cited by 140
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy
Subramaniyan, V., Chakravarthi, S., Jegasothy, R., Wu, Y. S., Fuloria, N. K., Fuloria, S., Hazarika, I., & Das, A. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.02.010 · Cited by 138
Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review
Aghemo, A., Alekseeva, O. P., Angelico, F., Бакулин, И. Г., Бакулина, Н. В., Bordin, D. S., Bueverov, A. O., Drapkina, O. M., Gillessen, A., Kagarmanova, E. M., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2069854 · Cited by 138
Roussel uclaf causality assessment method for drug-induced liver injury: Present and future
Danan, G., & Teschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00853 · Cited by 111
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults
Stättermayer, A. F., Halilbasic, E., Wrba, F., Ferenci, P., & Trauner, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.036 · Cited by 120
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19
Muhovic, D. F., Bojovic, J. B., Bulatović, A., Vukčević, B., Ratković, M., Lazović, R., & Smolović, B. (2020) · Liver International · doi:10.1111/liv.14516 · Cited by 119
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 118
Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review
Li, M., Luo, Q., Tao, Y., Sun, X., & Liu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.806249 · Cited by 116
Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
Meunier, L., & Larrey, D. G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01482 · Cited by 112
Self-citation
Acetaminophen-induced liver injury: Molecular mechanism and treatments from natural products
Liao, J., Lu, Q., Li, Z., Li, J., Zhao, Q., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122632 · Cited by 111
Herb-induced liver injury: Systematic review and meta-analysis
Ballotin, V. R., Bigarella, L. G., Brandão, A. B. D. M., Balbinot, R. Â., Balbinot, S. S., & Soldera, J. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i20.5490 · Cited by 110
Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury
Schneider, K. M., Elfers, C., Ghallab, A., Schneider, C. V., Galvez, E. J. C., Mohs, A., Gui, W., Candels, L. S., Wirtz, T. H., Zuehlke, S., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.11.002 · Cited by 108
ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18
Zhao, C. X., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C. X., & Shang, H.-C. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab503 · Cited by 108
Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management
Pi, B., Wang, J., Tong, Y., Yang, Q., Lv, F., & Yu, Y. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002280 · Cited by 105
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
Olry, A., Meunier, L., Delire, B., Larrey, D. G., Horsmans, Y., & Louët, H. L. (2020) · Drug Safety · doi:10.1007/s40264-020-00954-z · Cited by 102
Self-citation
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
Hountondji, L., Matos, C. F. D., Lebossé, F., Quantin, X., Lesage, C., Palassin, P., Rivet, V., Faure, S., Pageaux, G., Assénat, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100719 · Cited by 101
Self-citation
Approach to the patient with acute severe autoimmune hepatitis
Rahim, M. N., Miquel, R., & Heneghan, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100149 · Cited by 95
Chemotherapy-associated steatohepatitis
Meunier, L., & Larrey, D. G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2019.11.012 · Cited by 94
Self-citation
Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury
Rodriguez, C., Taminiau, B., García-García, A., Cueto‐Sánchez, A., Robles‐Díaz, M., Ortega‐Alonso, A., Martín‐Reyes, F., Daube, G., Sanabria‐Cabrera, J., Pérez, M. J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106348 · Cited by 94
Self-citation
Drug-induced liver injury in older people
Lucena, M. I., Sanabria, J., García-Cortes, M., Stephens, C., & Andrade, R. J. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30006-6 · Cited by 77
Self-citation
Drug‐induced peripheral oedema: An aetiology‐based review
Largeau, B., Cracowski, J., Lengellé, C., Sautenet, B., & Jonville‐Béra, A. ‐. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14752 · Cited by 89
Aflatoxin B1-induced hepatotoxicity through mitochondrial dysfunction, oxidative stress, and inflammation as central pathological mechanisms: A review of experimental evidence
Moloi, T. P., Ziqubu, K., Mazibuko-Mbeje, S. E., Mabaso, N. H., & Ndlovu, Z. (2024) · Toxicology · doi:10.1016/j.tox.2024.153983 · Cited by 89
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Self-citation
Liver involvement is not associated with mortality: results from a large cohort of SARS‐CoV‐2‐positive patients
Ponziani, F. R., Zompo, F. D., Nesci, A., Santopaolo, F., Ianiro, G., Pompili, M., Gasbarrini, A., & “Gemelli against COVID‐19” group (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15996 · Cited by 85
Polygenic architecture informs potential vulnerability to drug-induced liver injury
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1023-0 · Cited by 84
Self-citation
Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics
Shi, S., Wang, X., van der Laan, L. J. W., Pan, Q., & Verstegen, M. M. A. (2021) · Transplantation · doi:10.1097/tp.0000000000003691 · Cited by 84
Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 84
Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports
Lombardi, N., Crescioli, G., Maggini, V., Ippoliti, I., Menniti‐Ippolito, F., Gallo, E. R., Brilli, V., Lanzi, C., Mannaioni, G., Firenzuoli, F., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14460 · Cited by 83
Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China
Zhu, L., Zhang, C., Li, D.-P., Chen, H., Ma, J., Gao, H., Ye, Y., Wang, J.-Y., Fu, P. P., & Lin, G. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00553-9 · Cited by 81
Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?
Tan, C. K., Wong, Y. J., Wang, L. M., Ang, T. L., & Kumar, R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.009 · Cited by 81
Drug‐Induced Liver Injury in GI Practice
Sandhu, N., & Navarro, V. J. (2020) · Hepatology Communications · doi:10.1002/hep4.1503 · Cited by 78
Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study
Hao, S.-R., Zhang, S.-Y., Lian, J., Jin, X., Ye, C.-Y., Cai, H. Q., Zhang, X., Hu, J.-H., Zheng, L., Zhang, Y.-M., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000717 · Cited by 78
Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events
Gustot, T., Stadlbauer, V., Laleman, W., Alessandria, C., & Thursz, M. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.005 · Cited by 74
Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies
Mizuno, K., Ito, T., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Kawashima, H., Inukai, Y., Toyoda, H., Yokota, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01677-9 · Cited by 73
Management of hepatotoxicity of chemotherapy and targeted agents.
Mudd, T. W., & Guddati, A. K. (2021) · PubMed Central · Cited by 71
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Self-citation
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
Björnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., et al. (2023) · Liver International · doi:10.1111/liv.15378 · Cited by 69
Self-citation
Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury
Liu, M., Huang, Q., Zhu, Y., Chen, L., Li, Y., Gong, Z., & Ai, K. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100215 · Cited by 69
Mitochondrial Dysfunction and Chronic Liver Disease
Zhang, C., Zhao, Y., Yu, M., Qin, J., Ye, B., & Wang, Q. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44070218 · Cited by 68
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 68
The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury
Fontana, R. J., Bjornsson, E. S., Reddy, K. R., & Andrade, R. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.040 · Cited by 68
Self-citation
Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
Brennan, P., Cartlidge, P., Manship, T. A., & Dillon, J. F. (2021) · Frontline Gastroenterology · doi:10.1136/flgastro-2021-101886 · Cited by 66
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Lee, B. P., Witkiewitz, K. A., Mellinger, J. L., Anania, F. A., Bataller, R. A., Cotter, T. G., Curtis, B. L., Dasarathy, S., DeMartini, K. S., Diamond, I., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00936-x · Cited by 65
Biologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Acute liver failure
Vasques, F., Cavazza, A., & Bernal, W. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000923 · Cited by 64
Systematic review: ibuprofen‐induced liver injury
Zoubek, M. E., Lucena, M. I., Andrade, R. J., & Stephens, C. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15645 · Cited by 64
Self-citation
An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury
Lodato, F., Larocca, A., D’Errico, A., & Cennamo, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.005 · Cited by 63
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Clinical standards for the management of adverse effects during treatment for TB
Singh, K. P., Carvalho, A. C., Centis, R., D´Ambrosio, L., Migliori, G. B., Mpagama, S. G., Nguyen, B. C., Aarnoutse, R. E., Aleksa, A., van Altena, R., et al. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0078 · Cited by 62
Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Self-citation
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 60
Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review
Benić, M. S., Nežić, L., Vujić‐Aleksić, V., & Mititelu-Tarțău, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785790 · Cited by 59
Clinical management of patients with drug‐induced liver injury (DILI)
Bjornsson, E. S. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12113 · Cited by 58
Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases
Xing, M., Gao, M., Li, J., Han, P., Mei, L., & Zhao, L. (2022) · Medicine · doi:10.1097/md.0000000000028443 · Cited by 58
N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review
Sanabria‐Cabrera, J., Tabbai, S., Niu, H., Álvarez‐Álvarez, I., Licata, A., Bjornsson, E. S., Andrade, R. J., & Lucena, M. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876868 · Cited by 58
Self-citation
Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice
Andrade, R. J., & Robles‐Díaz, M. (2019) · Liver International · doi:10.1111/liv.14271 · Cited by 58
Self-citation
EASL Clinical Practice Guidelines on vascular diseases of the liver
Rautou, P., Moga, L., Hernández–Gea, V., Walter, A., Murad, S. D., García‐Pagán, J. C., Guido, M., McLin, V. A., Tripathi, D., & Vilgrain, V. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.001 · Cited by 57
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19
Yip, T. C., Wong, V. W., Lui, G. C.-Y., Chow, V. C., Tse, Y., Hui, V. W., Liang, L. Y., Chan, H. L., Hui, D. S. C., & Wong, G. L. (2021) · Hepatology · doi:10.1002/hep.31890 · Cited by 56
Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review
Robles‐Díaz, M., Nežić, L., Vujić‐Aleksić, V., & Bjornsson, E. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.744488 · Cited by 56
Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver
Bessone, F., Hernández, N., Tagle, M., Arrese, M. A., Paraná, R., Méndez‐Sánchez, N., Ridruejo, E., Mendizábal, M., Dagher, L., Contreras, F., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100321 · Cited by 56
Long-term sequelae of drug-induced liver injury
Bjornsson, E. S., & Andrade, R. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.011 · Cited by 54
Self-citation
Review article: liver disease in adults with variants in the cholestasis‐related genes ABCB11 , ABCB4 and ATP8B1
Nayagam, J. S., Williamson, C., Joshi, D., & Thompson, R. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16118 · Cited by 53
Liver Histology
Gasmi, B., & Kleiner, D. E. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.09.004 · Cited by 53
In Vitro Models for Studying Chronic Drug-Induced Liver Injury
Donato, M. T., Ferrer, G. G., & Tolosa, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911428 · Cited by 52
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Biolato, M., Bianco, A. D., Lucchini, M., Gasbarrini, A., Massimiliano Mirabella, A., & Grieco, A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00842-9 · Cited by 52
Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
Wong, C. K. H., Mak, L., Au, I. C. H., Lai, F. T. T., Li, X., Wan, E. Y. F., Chui, C. S. L., Chan, E. W., Cheng, W. Y., Cheng, F. W. T., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.032 · Cited by 51
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 51
Metamizole: An underrated agent causing severe idiosyncratic drug‐induced liver injury
Sebode, M., Reike‐Kunze, M., Weidemann, S. A., Zenouzi, R., Hartl, J., Peiseler, M., Liwinski, T., Schulz, L., Weiler‐Normann, C., Sterneck, M. R., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14254 · Cited by 50
Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms
Rana, P., Aleo, M. D., Wen, X., & Kogut, S. J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.028 · Cited by 50
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni, G., Kirchner, T., Engel, B., Villamil, A. M., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., Lleo, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100605 · Cited by 37
Self-citation

Authors: Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
ORCID: Andrade, Raúl J.
Aithal, Guruprasad P.
Kaplowitz, Neil
Kullak-Ublick, Gerd A.
Larrey, Dominique
Karlsen, Tom H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2019-06
Volume: 70
Issue: 6
Pages: 1222-1261
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2019.02.014
OpenAlex: W2924328881
Semantic Scholar: 6d774d1c570eef200451a1e8a8f5655c367a4eaf
Cited by: 1,276
References: 371
Citations by year: 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
FWCI: 78.91
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Funders: European Cooperation in Science & Technology
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
MeSH terms: Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EASL Clinical Practice Guidelines: Drug-induced liver injury

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks